Objective To investigate the cost-effect of Vancomycin and Linezolid in the treatment of MRSA infection, providing practical basis for clinical drug use. Methods Patients admitted into our hospital duringfrom January 2014 to March 2016 were retrospectively analyzed. All cases of MRSA infection using Vancomycin or (and) Linezolid as antibiotic therapy were included in this study. The efficacy and pharmacogenomics of Linezolid and Vancomycin in treatment of MRSA were recorded. Results Incidence of renal function in linezolid Linezolid group was significantly lower than that in Vancomycin group (P < 0.05). Time duration of antibiotics usage in Vancomycin group were prolonged compared with linezolid Linezolid group [(7.04 ± 0.45) d vs (5.12 ± 0.47), P < 0.05]. Longer hospitalization stay was also identified in Vancomycin group compared with Linezolid group [(10.76 ± 0.53) d vs (8.06 ± 0.58) d, P < 0.05]. DUI of Vancomycin and Linezolid were both less than 1, while therapeutic effectiveness and cost-effectiveness ratio (C/E) of Linezolid was significantly higher than that in Vancomycin group (P < 0.05).Conclusion Linezolid may be a better choice for treatment of MRSA due to better cost-effectiveness, efficacy and safety compared with Vancomycin.

目的 调查胃息肉患者的病例资料,评估胃息肉的危险因素,为胃息肉的防治提供理论依据.方法 选择2014年1月至2016年1月在西安医学院第一附属医院接受胃镜检查确诊为胃息肉的110例患者作为胃息肉组,选择同期因消化系统疾病接受胃镜检查排除胃息肉的101例患者作为对照组,回顾性分析患者的一般资料、伴有疾病、职业特点和幽门螺杆菌(Hp)检测结果等数据,采用χ2检验评估胃息肉发生发展的相关因素.结果 胃息肉组与对照组患者的性别、年龄、职业特点和Hp阳性率差异无统计学意义;胃息肉组患者中约40.91%体质量指数异常,在体质量指数异常患者中,超重和肥胖患者占82.20%;胃息肉组患者中伴有窦性心动过缓、脂肪肝、慢性胃炎和胆囊炎的患者,胃息肉发生率均高于对照组(P均<0.05).结论 胃息肉发生可能与体质量超重、伴有窦性心动过缓、脂肪肝、慢性胃炎和胆囊炎等因素相关.